ArticleChest2026
Incidence of New Comorbidities After Steroid Use in Patients With Sarcoidosis: An International Cross-Sectional Survey.
Article in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nonsteroid treatment options in (pulmonary) sarcoidosis. When to consider and why?Current opinion in pulmonary medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundOral corticosteroids (OCSs) are recommended as first-line therapy for sarcoidosis, yet limited data describe the risk of steroid-associated adverse effects in this population. RESEARCH QUESTION: What are the short-term and long-term effects of OCS exposure in terms of developing steroid-related comorbidities in a multinational cohort with sarcoidosis? STUDY DESIGN AND
methodsAn electronic questionnaire was codeveloped and translated by an international team of sarcoidosis experts and patients from the United States and Europe. We used inverse probability weighting to estimate the average treatment effect on the treated adjusted for markers of disease severity. Before data collection, we prespecified 2 primary outcomes: (1) development of 13 steroid-associated comorbidities and (2) total weight change. Outcomes were compared across patients with OCS exposure categorized as current, past, or never.
resultsWe collected self-reported questionnaires from 1,937 patients with sarcoidosis representing 34 countries. In weighted analyses, ever use of OCSs (current or past OCS use) was associated with development of 1.3 more comorbidities (95% CI, 0.8-1.9) compared with never using OCSs. Ever use of OCSs was associated with increased odds for the development of mood changes (OR, 2.1; 95% CI, 1.3-3.4), gastroesophageal reflux disease (OR, 2.3; 95% CI, 1.3-4.1), bruising (OR, 2.3; 95% CI, 1.3-4.1), osteoporosis (OR, 3.8; 95% CI, 1.8-8.1), hyperlipidemia (OR, 1.9; 95% CI, 1.04-3.5), infections (OR, 2.1; 95% CI, 1.1-4.0), and diabetes (OR, 2.7; 95% CI, 1.2-6.0). Ever use of OCSs was associated with 5.9 kg (95% CI, 3.8-8.0 kg) more net weight gain than never use. The effects of OCS use were more pronounced between ever and never OCS users and were similar between current and past OCS users.
interpretationEver use of OCSs was associated with multiple steroid-related comorbidities and weight gain in patients with sarcoidosis. Notably, adverse effects persisted even after OCS discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.